NeuroVive's cardiology candidate fails to meet its endpoint

NeuroVive's candidate for aiding in recovery after severe heart attacks failed to meet its endpoint following a topline analysis. "While the primary endpoint of the CIRCUS study has not been met, analysis of the full 12-month data set will provide us with more information in regard to which patients may have benefited from treatment with CicloMulsion. These results will help define next steps in the development and commercialization of CicloMulsion. The CIRCUS study is an independent, investigator-led study and we will continue to collaborate with the lead investigator to further evaluate the full 12-month study results as they become available," said NeuroVive CEO Mikael Brönnegård. CicloMulsion is a cremophor-free lipid emulsion formulation of cyclosporine. More

Suggested Articles

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.

Researchers at Johns Hopkins have changed the structure of a new cancer drug to allow it to more easily pass the blood-brain barrier, giving it access to…

Medtronic’s world-first FDA-approved hybrid closed-loop insulin delivery system might soon face competition, as T1D Exchange has pledged to invest in the…